BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary ...
Anika Therapeutics, Inc., (NASDAQ: ANIK), a leader in products for tissue protection, healing, and repair based on hyaluronic acid (HA) technology, today reported positive results from the CINGAL ® 13 ...
It’s turned out to be a challenging 2018 for Anika Therapeutics’ new CEO Joseph Darling—and a failed phase 3 trial for lead pipeline drug Cingal won’t make his job any easier. The study in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results